Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Chronic Myelomonocytic Leukemia (AGMT_CMML 1)
NCT01368757Phase 2Unknown
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Jun 2010
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in chronic myelomonocytic leukemia (CMML), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01368757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368757.